Finasteride on TRT: DHT Blocking, Hair Loss, and What Men Actually Need to Know

Separate Hair-Loss Diagnosis From a Blood DHT Result

Testosterone can be converted to dihydrotestosterone (DHT) by 5-alpha reductase. Finasteride inhibits the type II enzyme. The relationship between a blood measurement and a particular tissue's androgen activity is more complex than assuming that twice the serum testosterone creates twice the scalp DHT. A clinical review emphasizes that circulating and intracellular androgen concentrations are distinct. [1]

Male-pattern baldness has substantial genetic contributions. The Heilmann-Heimbach meta-analysis included 10,846 early-onset cases and 11,672 controls from eight cohorts and identified 63 associated loci. It does not establish one genetic test that predicts every man's hair response to TRT. [2]

If hair changes after TRT starts, record the timeline and pattern. Gradual recession or vertex thinning, diffuse shedding and an irritated scalp raise different diagnostic questions. Family history is useful context, but neither family history nor a single DHT result substitutes for examining the scalp. The practical goal is to identify what is changing before adding or changing a medicine.

What Oral Finasteride Trials Actually Show

In a 42-day dose study of 249 men with androgenetic alopecia, finasteride 1 mg reduced scalp DHT by 64.1% and serum DHT by 71.4%. These are study averages in that population, not a guaranteed percentage for a man receiving exogenous testosterone. [3]

Two one-year hair-loss trials randomized 1,553 men aged 18 to 41; 1,215 continued into a second year. Hair counts, assessments and photographs favored finasteride over placebo. That supports treating male-pattern hair loss, but it does not prove that a particular percentage of men on TRT will keep all their hair. [4]

The Propecia label specifies 1 mg once daily for male-pattern hair loss. Clinical response takes months rather than following the rapid change in a hormone concentration. [5] Track comparable photographs and the same affected area over time; a change in lighting, hair length or styling can look like a treatment response when it is not.

Does Blocking DHT Remove Testosterone's Benefits?

The available combination trials give a more specific answer than a general claim that finasteride either preserves or blunts every effect of TRT.

Page and colleagues randomized 70 men aged at least 65 with low testosterone to testosterone enanthate, testosterone plus finasteride 5 mg, or placebo for 36 months; 50 completed the protocol. Physical performance, grip strength and lean mass improved with testosterone both with and without finasteride. [6]

Another randomized trial studied 60 men aged at least 60 for 52 weeks, using testosterone enanthate 125 mg weekly and finasteride 5 mg daily in a factorial design. Finasteride did not alter the measured musculoskeletal and body-composition effects and prevented the testosterone-related prostate enlargement observed in that trial. [7]

Both studies used 5 mg finasteride and selected older populations. Their findings cannot establish the hair outcome, sexual response or long-term experience of every man using 1 mg with a different TRT formulation. Use the outcome actually measured rather than extending a muscle or prostate result to an unmeasured symptom.

Formulation Differences Do Not Establish a Hair-Saving Injection Schedule

A historical meta-analysis of 32 studies involving 1,152 men found greater serum-DHT elevation with transdermal than intramuscular testosterone. The studies differed in products and regimens. This comparison does not establish that changing an individual from gel to injection prevents hair loss, or that one injection ester is best for the scalp. [8]

The current cypionate label describes an approximately eight-day half-life after intramuscular injection and specifically distinguishes cypionate from propionate. [9] Half-life alone cannot establish equivalent doses, an appropriate route, a scalp-DHT peak or a home switching plan.

For cypionate, enanthate, propionate or pellets, the useful comparison is the actual prescription, measured testosterone response, symptoms, convenience and ability to adjust treatment. A claim that twice-weekly injections reduce peak DHT by 38%, or that pellets always cause less hair loss, needs direct evidence for that regimen and endpoint. The sources reviewed here do not establish those rules. Discuss a proposed prescription change with the TRT prescriber instead of converting a pharmacokinetic estimate into a dose instruction.

Prepare a Treatment Comparison for the Appointment

This comparison organizes the information a clinician needs. It does not assign a risk tier or determine who should receive oral finasteride, a topical preparation or a different TRT schedule. If several treatments change together, interpreting the next photograph or symptom change becomes harder.

Topical Finasteride Has Formulation-Specific Evidence

A 24-week topical-finasteride spray trial randomized 458 men, with 323 completing the study and 446 assessed for safety. Target-area hair count improved by 20.2 hairs with topical treatment versus 6.7 with placebo. The oral comparator's improvement was numerically similar; that wording does not establish formal noninferiority. [10]

Maximum plasma finasteride concentrations were more than 100 times lower with the topical spray. Mean serum-DHT reduction was 34.5% with topical versus 55.6% with oral treatment. Systemic suppression was reduced, not absent. The participants were not a TRT-specific population, and the findings should not be generalized to every compounded concentration, amount or delivery system. [10]

When comparing a topical option, identify the actual formulation and prescribed application. A percentage on a bottle is not enough to establish equivalence to a studied spray or to predict a person's systemic exposure.

Interpret Sexual and Persistent-Symptom Evidence Carefully

The Propecia label's first-year hair-loss trials reported one or more sexual adverse events in 3.8% of users versus 2.1% with placebo, including erectile dysfunction in 1.3% versus 0.7%. Those are alopecia-trial rates, not measured rates for the combination with TRT. The label also records persistent sexual symptoms and depression reported after marketing; such reports cannot reliably establish their frequency or causality. [5]

The cited Melcangi study examined neuroactive steroids in three selected post-finasteride patients and five controls. Its exploratory findings cannot estimate how often persistent symptoms occur or prove one mechanism for all patients. [11]

A new sexual, mood or breast symptom deserves an individual review of its timing and the whole regimen. Neither an adequate testosterone result nor a low DHT result identifies the cause on its own. Record which symptom changed and when, rather than assuming that TRT prevents finasteride-related symptoms or that every symptom is caused by finasteride.

Keep TRT Monitoring and PSA Interpretation Specific

The Endocrine Society guideline calls for a standardized TRT follow-up plan that assesses symptoms, adverse effects, adherence, testosterone, hematocrit and prostate risk during the first year. It does not turn an identical DHT, estradiol and lipid schedule into a requirement for every man adding finasteride. [12] The cypionate label separately calls for periodic hemoglobin and hematocrit checks during long-term androgen treatment. [9]

Finasteride affects PSA interpretation. The Propecia label reports mean PSA changing from 0.7 to 0.5 ng/mL after 12 months in younger men taking 1 mg. The approximately 50% reduction described for 5 mg in older BPH patients should not be applied as an automatic doubling rule to every 1 mg result. Tell the clinician interpreting PSA about the actual product, dose and duration. [5]

The reviewed sources do not establish a universal blood-DHT target of less than 40 pg/mL for hair protection on combined therapy. If a test is ordered, ask what decision it will inform and how units, the laboratory range and the current regimen will be interpreted.

Compare Alternatives by Their Actual Evidence

In a 24-week BPH trial of 399 patients, dutasteride 0.5 mg suppressed serum DHT more than finasteride 5 mg. The study did not establish a superior hair response or a higher sexual-side-effect rate for men on TRT. [13] Stronger hormone suppression is not automatically the outcome a particular patient needs.

Minoxidil is a separate hair-treatment option rather than another DHT blocker. A review of oral minoxidil covered 17 studies and 634 patients, with heterogeneous designs and limited large-trial evidence. [14] Oral and topical treatment are different decisions; the prescription and formulation matter.

If considering a device or procedure, ask which hair-loss diagnosis, outcome and follow-up its evidence addresses. Compare that with medication options without assuming that avoiding a DHT blocker guarantees a particular result.

Reassess the Actual Goal

Finasteride and TRT address different treatment goals. A useful follow-up compares the same scalp area, symptoms and actual prescription over time. Keep blood-hormone changes, hair outcomes and other TRT benefits separate when interpreting the evidence. That makes the next treatment discussion more informative than using a universal DHT target, an unsupported injection schedule or an unmeasured regrowth percentage.